| Name | Title | Contact Details |
|---|---|---|
sandeep angra |
Chief Information Technology Officer | Profile |
9to5 Seating is a vertically-integrated, privately owned company, founded in 1986, which specializes in the design and production of ergonomic office seating to accommodate the rigorous demands of todays office environments. 9to5 Seating presents an extensive collection of executive, task, guest, conference, stool and lounge seating. Customization is an everyday demand that 9to5 Seating welcomes; seats, controls, arms, chair adjustments, finishes, and upholstery options are plentiful. 9to5 Seating combines its state-of-the-art, in-house manufacturing systems with a commitment to continuous improvements in all phases of the operation. With over 500,000 sq. ft. of manufacturing resources, we are confidently empowered to deliver products offered at unparalleled pricing, with quality built into every phase of manufacturing. Our dedication to becoming the leader in office furniture requires that we go beyond customer expectations. We strive to provide quality products, plethora of upholstery options, express shipping superior customer service and the best warranty as possible.
Stellar is a manufacturer and distributor of domestic hydraulic hook-lift hoist and accessories.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.